Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

ABSTRACT: There have been no recent advances in drug development for mood disorders in terms of identifying drug targets that are mechanistically distinct from existing ones. As a result, existing antidepressants are based on decades-old notions of which targets are relevant to the mechanisms of antidepressant action. Low rates of remission, a delay of onset of therapeutic effects, continual residual depressive symptoms, relapses, and poor quality of life are unfortunately common in patients with mood disorders. Offering alternative options is requisite in order to reduce the individual and societal burden of these diseases. The glutamatergic system is a promising area of research in mood disorders, and likely to offer new possibilities in therapeutics. There is increasing evidence that mood disorde

SUBMITTER: Machado-Vieira R 

PROVIDER: S-EPMC2795357 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature